84-14-06

IW

CERTIFICATE OF MAILING BY "EXPR	Docket No.						
Applicant(s): Durley et al P	PC28012						
Serial No. 10/808,146 APR 1 3 2006 March 24, 2004	Examiner	Group Art Unit					
10/808,146 (3 ATT 1.8 2006 March 24, 2004	Deepak R. Rao	1624					
Invention: SUBSTITUTED PYROVIDINONES							
OE (III)							
I hereby certify that this Amend A, Amend. Trai	ns. Ltr, Rtn Postcard, Replacement Pg	335 CRF & Por Sea List					
Thereby certify that this Amend A, Amend. 11 a	(Identify type of correspondence)	, 333, CKF & FPF Seq List					
is being deposited with the United States Postal	Service "Express Mail Post Office to	Addressee" service under					
37 CFR 1.10 in an envelope addressed to: The	e Commissioner of Patents and Trac	lemarks, Washington, D.C.					
20231-0001 on April 13, 2006							
(Date)							
Michelle R. Becker							
	(Typed or Printed Name of Person Mailing Correspondence)						
	M. Iller						
	(Signature of Person Mailing Correspondence)						
	EV 580754567 US						
	("Express Mail" Mailing I	Label Number)					
Note: Each paper n	must have its own certificate of mailing.						

Wy Kine

AMENDMENT TRANSMITTAL LETTER (Large Entity) Applicant(s): Durley et al. P.						Docket No. PC28012		
Serial No. 10/808,146	Serial No.		D	Examiner Deepak R. Rao		Group Art Unit 1624		
Invention: SUBSTITUTED PYRISHIDINONES								
TO THE ASSISTANT COMMISSIONER FOR PATENTS: Transmitted herewith is an amendment in the above-identified application.								
	calculated and is transi		• •	1011.				
CLAIMS AS AMENDED								
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST #	NUME	BER EXTRA	RATE	ADDITIONAL FEE		
TOTAL CLAIMS	17 -	70 =		0	x \$18.			
INDEP. CLAIMS	1 -	3 =		0	x \$80.	.00 \$0.00		
Multiple Depender	nt Claims (check if appl	licable)				\$0.00		
		TOTAL ADDITIO	NAL FEE FO	OR THIS AM	ENDMENT	\$0.00		
 No additional fee is required for amendment. □ Please charge Deposit Account No. in the amount of A duplicate copy of this sheet is enclosed. □ A check in the amount of to cover the filing fee is enclosed. ☑ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-1025 A duplicate copy of this sheet is enclosed. ☑ Any additional filing fees required under 37 C.F.R. 1.16. ☑ Any patent application processing fees under 37 CFR 1.17. 								
Julie M. Lappin Reg. No. 46,612	Signature		Dated:	otapril 13, 2006 first class ma	t this docum 6 iil under 37 C.	nent and fee is being deposited with the U.S. Postal Service as .F.R. 1.8 and is addressed to the for Patents, Washington, D.C.		

Signature of Person Mailing Correspondence

Michelle R. Becker

Typed or Printed Name of Person Mailing Correspondence

Application/Control No. Applicant(s) 10/808,146 Examiner Rao, D. Application/Control No. Applicant(s) DURLEY, RICHARD C. Art Unit Rao, D. 1624

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or

unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: .

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

Patentin Software Program Support

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

U.S. Patent and Trademark Office

Part of Paper No. 03202006